Alloantigenicity of Human Endothelial Cells. 1. Frequency and Phenotype of Human T Helper Lymphocytes That Can React to Allogeneic Endothelial Cells
Overview
Affiliations
To determine the relative ability of allogeneic endothelial cells to stimulate helper T lymphocytes (HTL), human PBMC or purified T cells were incubated in conventional lymphocyte microcultures or in limiting dilution microcultures with allogeneic human umbilical vein endothelia (HUVE), with cytokine-treated allogeneic HUVE, or with allogeneic peripheral blood monocytes. These cultures were tested for IL-2 production as an index of HTL stimulation. Dose-response studies in conventional lymphocyte cultures indicated that allogeneic monocytes were better than allogeneic HUVE at stimulating IL-2 production. Limiting dilution analyses revealed that untreated HUVE and TNF-treated HUVE stimulated small numbers of HTL (approximately 1 HTL/30,000 PBMC), whereas 5 to 10 times more HTL were stimulated by IFN-gamma-treated HUVE and 10 to 20 times more HTL were stimulated by allogeneic monocytes. Serologic deletion studies revealed that most of the high frequency HTL responding to IFN-gamma-treated HUVE were CD4+, whereas most of the low frequency HTL responding to nontreated HUVE or to TNF-treated HUVE were CD8+. Interestingly, mAb to MHC class I and class II molecules, which significantly impaired HUVE-induced proliferation, caused little interference with HUVE-induced IL-2 production. Finally, polymerase chain reaction analysis demonstrated that untreated allogeneic HUVE cells could stimulate PBMC to produce mRNA for IFN-gamma, as well as for IL-2. These data demonstrate the following hierarchy of allogeneic stimulatory capacity for human HTL: monocytes greater than IFN-gamma-treated HUVE much greater than TNF-treated HUVE = nontreated HUVE. Further, these data suggest that non-activated allogeneic endothelial cells can initiate immune responses by inducing IL-2 and IFN-gamma. Because IFN-gamma can induce MHC class II expression by the endothelial cells, this could recruit large numbers of CD4+ T cells for IL-2 production.
Endothelial activation, lymphangiogenesis, and humoral rejection of kidney transplants.
Phillips S, Kapp M, Crowe D, Garces J, Fogo A, Giannico G Hum Pathol. 2016; 51:86-95.
PMID: 27067786 PMC: 5832366. DOI: 10.1016/j.humpath.2015.12.020.
Blocking MHC class II on human endothelium mitigates acute rejection.
Abrahimi P, Qin L, Chang W, Bothwell A, Tellides G, Saltzman W JCI Insight. 2016; 1(1).
PMID: 26900601 PMC: 4756651. DOI: 10.1172/jci.insight.85293.
Diversity of the CD4 T Cell Alloresponse: The Short and the Long of It.
Ali J, Negus M, Conlon T, Harper I, Qureshi M, Motallebzadeh R Cell Rep. 2016; 14(5):1232-1245.
PMID: 26804905 PMC: 5405053. DOI: 10.1016/j.celrep.2015.12.099.
Vascular endothelium as a target of immune response in renal transplant rejection.
Piotti G, Palmisano A, Maggiore U, Buzio C Front Immunol. 2014; 5:505.
PMID: 25374567 PMC: 4204520. DOI: 10.3389/fimmu.2014.00505.
Denton M, Geehan C, Alexander S, Sayegh M, Briscoe D J Exp Med. 1999; 190(4):555-66.
PMID: 10449526 PMC: 2195607. DOI: 10.1084/jem.190.4.555.